POPULARITY
Transcript [Music] I'm Susie Craig. Welcome to Food Safety in a Minute. Fruits and vegetables are a staple at farmers markets. Whole produce is safe to display and purchase, but pre-cut items like cantaloupe and watermelon should be refrigerated or kept on ice by vendors. After buying pre-cut items, store in a cooler or insulated bag at 40 degrees Fahrenheit or below for the trip home, then refrigerate promptly. Strawberries, blueberries, and raspberries should be refrigerated after purchase. Avoid rinsing berries before storage, as moisture promotes bacterial growth and spoilage. Leafy greens and mushrooms also require refrigeration due to their high moisture content, which makes them prone to mold and bacteria. To ensure food safety, rinse all produce under cool, running water before eating, reducing the risk of foodborne illness. This is Food Safety in a Minute from Washington State University Extension [Music] Resources United States Department of Agriculture – Food Safety.gov. Shopping at the Farmers Market with Food Safety in Mind. https://www.foodsafety.gov/blog/shopping-farmers-market-food-safety-mind. Accessed online 3/19/25. United States Food and Drug Administration. Selecting and Serving Produce Safely. https://www.fda.gov/food/buy-store-serve-safe-food/selecting-and-serving-produce-safely. Accessed online 3/19/25.
Dr. Boros holds a Doctor of Medicine (M. D.) degree from the Albert Szent-Györgyi School of Medicine, Szeged, Hungary and is a retired Professor of Pediatrics, Endocrinology and Metabolism of the University of California Los Angeles (UCLA) School of Medicine. Dr. Boros is the co-inventor of the stable isotope-based dynamic metabolic profiling (SIDMAP) technology, which is a functional biochemistry tool used for detailed biochemical and deutenomics related drug testing, library screening, lead optimization and in vitro and in vivo phenotype profiling. The core technology involves studying natural and disease/drug induced variations in stable non-radiating stable 13C (carbon) and 2H (deuterium) isotope distribution patterns and cross talk among metabolites in living systems. He also established mitochondrial quantum vacuum as the prime driving force of all life related energy producing biochemical events. These occur via the quantum destabilization of hydrogen ions, i. e. protons, in structured water of mitochondrial nano-confinements that are compromised by deuterium; hence the regulation of deuterium (deutenomics, human deutenome project) is a critical process to maintain health and longevity.Dr. Boros trained as a house staff in his medical school in gastroenterology after receiving a research training fellowship from the Hungarian Academy of Sciences. Dr. Boros was a visiting Scholar at the Essen School of Medicine in Germany and also worked as a Research Scientist at the Ohio State University, Department of Surgery. Dr. Boros is the recipient of the C. Williams Hall Outstanding Publication Award from the Academy of Surgical Research of the United States (1997), the Richard E. Weitzman Memorial Research Award from the University of California (2001), the Excellence in Clinical Research Award from the General Clinical Research Center at the Harbor-UCLA Medical Center (2004) and Public Health Impact Investigator Award of the United States Food and Drug Administration (2011). Dr. Boros serves as an associate editor for the journals Springer Nature- Scientific Reports, Medicine, Pancreas, Molecules and Metabolomics.SHOWNOTES:
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications. Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications. Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.
Would you take a test to find out your cancer risk? At-home genetic testing makes it easy, but experts warn that these tests may create more harm than good. A New Approach to Genetic Testing Genetic testing has traditionally been performed under the supervision of healthcare providers, with genetic counseling to help patients navigate their results. This approach ensures that individuals receive proper guidance, reducing the emotional and practical challenges of interpreting complex genetic information. In September 2023, the United States Food and Drug Administration (FDA) approved a new test called the Invitae Common Hereditary Cancers Panel. This test checks for changes in 48 genes linked to hereditary cancers, including breast, ovarian, and Lynch syndrome-related cancers. What makes it different is that it can be ordered online and taken at home with no doctor required. While the convenience of these tests is appealing, health experts have raised serious concerns. An editorial titled “Pitfalls and Perils from FDA-Approved Germ-line Cancer Predisposition Tests,” authored by Dr. Wafik S. El-Deiry, Editor-in-Chief of Oncotarget, and Dr. Eli Y. Adashi, both from Brown University, highlights the potential risks of using these tests without professional guidance. Full blog - https://www.oncotarget.org/2025/01/03/the-hidden-risks-of-at-home-genetic-cancer-tests/ Paper DOI - https://doi.org/10.18632/oncotarget.28677 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=DjKpiBNDWHo Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28677 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cancer predisposition, germline, marketing authorization, hereditary cancer, direct to consumer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to announce the submission of a comprehensive and updated Phase 2 Investigational New Drug clinical protocol to the United States Food and Drug Administration (FDA). This protocol aims to non-invasively treat basal cell carcinoma of the skin using micro-needle arrays containing doxorubicin, developed by Medicus Pharma's wholly owned portfolio company, Skinject, Inc. The submission features significant updates to the clinical protocol, including enhancements to the supporting Chemistry, Manufacturing, and Controls (CMC), along with detailed stability and sterility information. Furthermore, it addresses the clinical non-hold comments previously received from the FDA, ensuring a robust and thorough response to regulatory feedback. Dr. Bokhari shared with Proactive that the revised Phase 2 clinical protocol incorporates innovative elements such as artificial intelligence and confocal microscopy as supplementary endpoints at one of the clinical sites. These advanced technologies are expected to provide deeper insights and improved accuracy in the clinical outcomes. Medicus Pharma believes that this updated protocol is well-positioned to receive FDA approval, paving the way for the commencement of participant randomization potentially before the end of this quarter. This milestone underscores the company's commitment to advancing innovative treatments for skin cancer and improving patient outcomes through cutting-edge technology and rigorous clinical research. #proactiveinvestors #medicuspharmaltd #tsxv #mdcx #fda #clinicaltrials #RazaBokhari, #BasalCellCarcinoma, #CancerTreatment, #NonInvasive, #FDA, #ClinicalTrials, #AIinHealthcare, #ConfocalMicroscopy, #BiotechFunding, #Chemotherapeutics, #SkinCancer, #DrugDevelopment, #HealthcareInnovation, #MedicalResearch, #PatientCare, #ArtificialIntelligence, #MedicalAdvancements, #Pharmaceuticals, #TorontoStockExchange, #HealthcareTech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S. District Court for the Northern District of Texas, Amarillo Division, against the United States Food and Drug Administration (FDA) on behalf of the Alliance of Hippocratic Medicine (AHM) and others. The suit challenged the FDA's 2000 decision to legalize mifepristone […]
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S. District Court for the Northern District of Texas, Amarillo Division, against the United States Food and Drug Administration (FDA) on behalf of the Alliance of Hippocratic Medicine (AHM) and others.The suit challenged the FDA’s 2000 decision to legalize mifepristone and misoprostol, two drugs often used in conjunction as chemical abortifacients, and regulation of the drugs thereafter. The case rose through the Fifth Circuit, which ruled in favor of AHM. The Supreme Court granted cert, heard Oral Argument on March 26, 2024, and on June 13, 2024, issued a 9-0 decision holding the plaintiffs lacked standing to challenge the FDA.Join us for a Courthouse Steps Decision program, where we will analyze this decision and its possible ramifications.Featuring:Adam Unikowsky, Partner, Jenner & Block LLPMegan M. Wold, Partner, Cooper & Kirk(Moderator) Prof. Teresa Stanton Collett, Professor and Director, Prolife Center, University of St. Thomas School of Law
Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, I am speaking with Rick Doblin, founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS).December of last year was a milestone for Doblin and MAPS, as the organization submitted a New Drug Application for MDMA Assisted Therapy to the United States Food and Drug Administration.Then, in the first week of January, the MAPS Public Benefit Corp announced its rebranding to Lykos Therapeutics and a $100 million Series A financing.Needless to say, it has been a pivotal period in the organization's history and a watershed moment for the revival of psychedelic medicine, science, and policy.In February, the FDA accepted the application and granted a priority review, putting the decision timeline at August of this year.That's just around the corner.And so much is still up in the air—of course the big question—will the FDA grant approval? But also so many granular details that will have significant downstream effects on the commercial rollout, access, and cost.* What language will be on the drug label? * What will the Risk Evaluation and Mitigation Strategy entail? * How will patients be able to access the drug? * What will the FDA say about the role of therapy?Among others.So, I wanted to sit down with Rick to talk about it and get his perspective on the organization's evolution, the path ahead, and, most importantly, the many uncertainties that hang in the balance.In this conversation, we discuss:* The importance of therapy in conjunction with MDMA (and his loathing of the acronym MDMA-AT)* The many regulatory and bureaucratic details that go into the FDA's decision and subsequent commercial rollout, including:* Drug labeling* Therapist credentialing * Risk Evaluation and Mitigation Strategies* The negotiations he's led with the FDA over the last 20 years* Lykos' goal of getting MDMA-Assisted Therapy FDA approved and MAPS' goal of getting MDMA federally legalized* The role of therapist's first-hand experience with MDMA and the regulatory battle of ensuring legal access to this group* His future humanitarian and scientific plansAnd much more.And now I bring you my conversation with Rick Doblin.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com
BUFFALO, NY- March 4, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer (mUC). In this new study, researchers Thomas M. Cardillo, Maria B. Zalath, Roberto Arrojo, Robert M. Sharkey, Serengulam V. Govindan, Chien-Hsing Chang, and David M. Goldenberg from Gilead Sciences and the Center for Molecular Medicine and Immunology investigated the utility of combining SG with platinum-based chemotherapeutics in TNBC, urinary bladder carcinoma (UBC), and small-cell lung carcinoma (SCLC). “Given recent FDA approval of SG in mTNBC and accelerated approval in mUC [metastatic urothelial cancer], as well as its demonstrated clinical activity in SCLC [11], we investigated the possibility of expanding use of SG through combinations with currently utilized chemotherapeutics for these disease indications.” SG plus carboplatin or cisplatin produced additive growth-inhibitory effects in vitro that trended towards synergy. Immunoblot analysis of cell lysates suggests perturbation of the cell-cycle and a shift towards pro-apoptotic signaling evidenced by an increased Bax to Bcl-2 ratio and down-regulation of two anti-apoptotic proteins, Mcl-1 and survivin. Significant antitumor effects were observed with SG plus carboplatin in mice bearing TNBC or SCLC tumors compared to all controls (P < 0.0062 and P < 0.0017, respectively) and with SG plus cisplatin in UBC and SCLC tumor-bearing animals (P < 0.0362 and P < 0.0001, respectively). These combinations were well tolerated by the animals. “Combining SG with platinum-based chemotherapeutics demonstrates the benefit in these indications and warrants further clinical investigation.” DOI - https://doi.org/10.18632/oncotarget.28559 Correspondence to - Thomas M. Cardillo - Thomas.Cardillo1@Gilead.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28559 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, sacituzumab govitecan, Trop-2, SN-38, carboplatin, cisplatin About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to share some significant news: the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company's lead small molecule drug candidate aimed at treating pericarditis, including recurrent pericarditis. This designation is a major validation of CardiolRx's potential in addressing a debilitating heart condition. Elsley explained that recurrent pericarditis is a serious heart disease characterized by symptoms that significantly impact patients' quality of life and physical activity. The FDA's decision to grant ODD underscores the potential of CardiolRx to improve the lives of individuals suffering from this condition. MAvERIC-Pilot is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease. Orphan Drug Designation is granted by the FDA to drugs or biological products intended to prevent, diagnose, or treat rare diseases or conditions affecting fewer than 200,000 people in the United States. This designation offers several benefits to sponsors, including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Additionally, products with ODD may qualify for accelerated regulatory review through Fast Track, Breakthrough Therapy, or Priority Review designations. This milestone represents a significant advancement for Cardiol Therapeutics and its efforts to develop innovative therapies for cardiovascular diseases. With CardiolRx currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, the ODD from the FDA further strengthens the company's position in advancing treatments for these conditions #proactiveinvestors #cardioltherapeuticsinc #nasdaq #crdl #tsx #crdl #PericarditisTreatment, #OrphanDrugDesignation, #HeartHealth, #MedicalInnovation, #RareDisease, #HealthcareNews, #ClinicalTrials, #FDAApproval, #Biopharmaceutical, #InflammationTreatment, #MedicalResearch, #HealthTech, #PatientCare, #MedicalAdvancements, #HeartDiseaseAwareness, #PublicHealth, #HealthcareIndustry, #Cardiology, #MedicalBreakthroughs, #DrugDevelopment, #HeartMedicine, #HealthcareUpdates, #MedicalScience, #HealthcareTechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Description: In this episode, the Cigar Hustlers dive into the legal landscape, unpacking the upcoming schedule unveiled by the U.S. Court of Appeals for the District of Columbia in the long-standing Cigar Association of America et al. v. United States Food and Drug Administration et al. lawsuit. Seven years in the making, this lawsuit filed by three cigar trade groups challenges the FDA's deeming regulations. Listeners get the latest scoop on industry shifts as Esteban Carreras, Perdomo, and Black Label Trading Co. all announce impending price increases for 2024. Meanwhile, the closing of Casa de Montecristo's Webster, Texas location by the end of December prompts contemplation about the evolving cigar retail landscape. Delving into industry expansions, the team discusses Cigars International's strategic plans for a new Pittsburgh area store, tapping into the market's pulse. The episode doesn't just stick to business updates; it ventures into intriguing news. Luciano Cigars teases enthusiasts with the imminent release of "Underrated" slated for January, sparking anticipation among aficionados. But the surprises don't end there – the hosts take a lighthearted turn, sharing quirky news from Florida. From a driver in custody sporting a truck labeled "Booty Patrol," as per the DeSoto County Sheriff's Office, to a Florida woman offering to toplessly decorate Christmas trees for $300, the hosts inject humor into the mix, proving that the world of cigars isn't just about regulations and price shifts. Join the Cigar Hustlers as they navigate the serious, the intriguing, and the downright unusual facets of the cigar world in this eclectic and informative episode. Stick Around at the end for a Bonus episode from Smoke on The Water Westin
In the vast world of health and wellness, few shine as brilliantly as Oliver Amdrup, the visionary founder of Puori. This episode promises a deep dive into the world of ingredient quality, the incredible benefits of omegas, and the secret behind what many aficionados deem as the best protein powder on the market (and I agree!). What we cover: -Oliver unravels the exceptional standards of ingredient quality in Denmark, contrasting them with the US and how we go about labels--Prepare to rethink what you consume! -Uncover the often under-discussed significance of omegas and the monumental impact they have on our overall wellness. -Discover the dedication, research, testing, and innovation that birthed Puori's game-changing protein powder. A blend that's not just about muscles, but overall health. With his deep knowledge, unwavering commitment to purity, and infectious passion for wellness, Oliver's insights will transform the way you view nutrition. This is not just another health talk; it's a revelation. Dive in, enrich your health journey, and get inspired by the best in the business. Resources: Puori Supplements and Protein Powder - use code HEALINGTHESOURCE for a discount
In July 2023, the United States Food and Drug Administration approved a birth control pill for over-the-counter use, meaning most consumers could buy it from a pharmacy without a prescription. The pill will likely be available sometime in 2024. To learn more about the progestin-only birth control that's approved for over-the-counter use, we talked with Dr. Amy Domeyer-Klenske. We discussed how the pill works, important safety considerations for people to know, and the remaining questions about how birth control without a prescription might affect availability and access for people in the U.S. Dr. Domeyer-Klenske is an obstetrician-gynecologist, director of the UW Ob-Gyn Division of Academic Specialists in Ob-Gyn, and president of the Wisconsin section of the American College of Obstetricians and Gynecologists. RESOURCES: Progestin-Only Birth Control - American College of Ob-Gyns FDA Approves First Nonprescription Daily Oral Contraceptive - US Food and Drug Administration Over-the-counter birth control is coming. Here's what to know about cost and coverage - National Public Radio Have a suggestion for a future episode? Let us know what health issues you'd like to learn about here! https://forms.gle/XaoArBtnxfHxA4Up7
Episode 149: COVID Vaccines UpdateFuture Dr. Williams presented an update on COVID-19 vaccines. This update is only for immunocompetent individuals, and it was recorded on August 24, 2023. Dr. Arreaza added comments and insight. Written by John Williams, MS4, Ross University School of Medicine. Editing by Hector Arreaza, M.D. You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Currently, there are two types of vaccines that have been approved by the FDA:Moderna and Pfizer developed mRNA vaccines.Novavax developed a lesser-known protein subunit vaccine.As of May 6, 2023, the vaccine developed by Johnson & Johnson has expired and is not available in the U.S.Novavax: This vaccine contains pieces (proteins) of the virus that causes COVID-19, the spike protein plus an adjuvant. It works by activating the immune system against the spike protein, so it will be ready to fight the actual virus when you get infected. Regardless of vaccine type, the shots are administered in the upper arm and have been demonstrated, for most people, to be safe and effective. There have now been hundreds of million vaccines administered in the US alone and the effectiveness of the vaccine to reduce the risks of severe illness, hospitalization, and death has been well documented. The most common side effects consist of mild to moderate cases of fever, chills, headache, and tiredness that are self-resolving.What is new about COVID-19 Vaccines?The updated vaccine is known as “bivalent”. This term is important because it refers to the vaccine's ability to confer protection against both the original COVID-19 virus as well as new variants Omicron BA.4 and BA.5. Rollout of the updated vaccine began in September 2022 for those aged 12 years and older and became widespread in March 2023 with approval granted for use in children aged 6 months – 4 years. Selected individuals over age 65 or those who are immunocompromised may receive additional doses to provide comparable and safe protection. The receipt of the updated vaccine supersedes any previous doses and provides coverage against the most recent known variants determined to be either most widespread or that have been projected to be more prevalent.Children aged 6 months – 4 years who received the original Pfizer vaccineThose who received either 2 or 3 doses of the original vaccine should receive 1 dose of the updated vaccine.Those who received 1 dose of the original vaccine should receive 2 doses of the updated vaccine.You are considered up to date if you have received 3 vaccine doses, including at least 1 updated dose.Children aged 5 years who received the original Pfizer vaccineThose who received 1+ doses of the original vaccine should receive 1 dose of the updated vaccine.You are considered up to date if you have received at least 1 updated dose.Children aged 6 months – 4 years who received the original Moderna vaccineThose who received either 2 or 1 dose(s) of the original vaccine should get 1 updated vaccine.Children aged 5 years who received the original Moderna vaccineThose who received either 2 or 1 dose(s) of the original vaccine should get 1 updated vaccine.Unvaccinated children 6 m-4 years should receive the new bivalent vaccine, 2 doses ofModerna or 3 doses of Pfizer, but if you are 5 years old and unvaccinated, you will receive 1 dose of Pfizer or 2 doses of Moderna.For 6-11 yo patients who have been vaccinated with 1 or more doses of monovalent (Moderna or Pfizer) will receive 1 dose of Bivalent Moderna or Pfizer. If you already received 2 monovalent doses and 1 bivalent dose, you are done, no more vaccines are needed. If you have not received any COVID-19 vaccine and you are in this age group (6-11 yo), you only need 1 bivalent dose, and you are done.>12 yo and Adults. If you received 1 or more doses of monovalent or if you are not vaccinated, you need 1 dose of bivalent (Pfizer or Moderna). If you already had 2 doses of monovalent and 1 dose of bivalent, you are done!An FDA advisory committee convened on June 15, 2023, to discern the importance for additional updates to the most recent COVID-19 vaccine series. It was determined that the latest circulating variant currently making rounds is from the Omicron group known as XBB. The committee decided it is prudent to proceed with a preference for the XBB 1.5 variant. The updated vaccine will be a monovalent version available in the Fall of 2023. As with the previous version, the FDA will provide strict oversight and safety monitoring of the vaccine._______________________________Conclusion: Now we conclude episode number 149, “COVID Vaccines Updates.” Future Dr. Williams explained that the bivalent COVID vaccines are currently recommended for unvaccinated patients, or for those who were previously vaccinated with monovalent vaccines. This episode focused on patients who are NOT immunocompromised. We encourage our audience to check the CDC website for recommendations about patients who are immunocompromised.As a clarification, our sub-intern, John Williams, has a great sense of humor and he claimed to be the composer of the music for many famous Hollywood movies. We don't doubt his musical talent, but we must make clear that it was a joke! This week we thank Hector Arreaza and John Williams. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Tin, Alexander, New COVID vaccine and booster shots for this fall to be available by end of September, CBS Texas, published online on August 9, 2023. https://www.cbsnews.com/texas/news/covid-vaccine-booster-xbb-variants-september-2023/, accessed on September 7/, 2023.Center for Disease Control and Prevention, Overview of COVID-19 Vaccines, updated May 23, 2023, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html, accessed on September 7, 2023.Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023, United States Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023, accessed on September 7, 2023.Royalty-free music used for this episode: Gushito - Latin Chill. Downloaded on July 29, 2023, from https://www.videvo.net/
The United States Food and Drug Administration (FDA) recently said that by law food makers are permitted to add sesame to their products. They also must identify sesame content in their foods on product packaging. Sesame is the seed of the sesamum or benne plant. It is used to make oil and the seeds themselves are often used on bread or baked goods. The seeds come in black and white colors. Sesame is used in many foods to add a nutty flavor or some crunch. But the American non-profit group, the Center for Science in the Public Interest (CSPI), says about 1.6 million people are allergic to the seeds. Someone who is allergic can get very sick after eating the seeds. People with the allergy usually learn to stay away from traditional foods that contain sesame.美国食品和药物管理局(FDA)最近表示,根据法律,食品制造商可以在其产品中添加芝麻。 他们还必须在产品包装上标明食品中的芝麻含量。芝麻是芝麻或芝麻植物的种子。 它用于制造油,种子本身通常用于面包或烘焙食品。 种子有黑色和白色。芝麻用于许多食品中以增加坚果味或松脆感。但美国非营利组织公共利益科学中心 (CSPI) 表示,约有 160 万人对这些种子过敏。 过敏的人吃了种子后可能会病得很重。 患有过敏症的人通常会学会远离含有芝麻的传统食物。The CSPI is protesting to the FDA about a law that went into effect in January. The Food Allergy Safety, Treatment, Education, and Research Act, known as FASTER, listed sesame as a major allergen requiring identification on packaging for the first time.↳ Some food companies made changes to their production centers in reaction to the new law. Some cut sesame use completely. Others, however, decided to add sesame to products that did not usually contain it. As long as they identified the sesame on the food packaging, they were obeying the law fully. The CSPI and other organizations argue that adding sesame to foods that did not contain it in the past limits food choices for allergic people.CSPI 就 1 月份生效的一项法律向 FDA 提出抗议。《食品过敏安全、治疗、教育和研究法案》(FASTER)首次将芝麻列为主要过敏原,需要在包装上进行标识。为了应对新法律,一些食品公司对其生产中心进行了调整。 有的完全切芝麻。 然而,其他人决定在通常不含芝麻的产品中添加芝麻。 只要他们识别出食品包装上有芝麻,就完全遵守了法律。CSPI 和其他组织认为,在过去不含芝麻的食物中添加芝麻限制了过敏人群的食物选择。Some food companies say it is too hard to prevent sesame from getting into some products, or it is too costly to change their production centers. It is easier to add sesame and identify it legally. Some restaurants are also adding sesame to their foods and noting it on menus or meal listings in order to meet the requirements of the food law. Robert Earl is a food safety advocate. He said the practice will put people with food allergies in danger of getting sick. “It puts our community at greater risk,” he said. Earl added that food companies and restaurants adding sesame to products reduces food choices.一些食品公司表示,很难阻止芝麻进入某些产品,或者改变生产中心的成本太高。 添加芝麻更容易合法识别。一些餐馆还在食物中添加芝麻,并在菜单或餐单上注明,以满足食品法的要求。罗伯特·厄尔 (Robert Earl) 是一位食品安全倡导者。 他说这种做法将使食物过敏的人面临生病的危险。 “这使我们的社区面临更大的风险,”他说。 厄尔补充说,食品公司和餐馆在产品中添加芝麻会减少食物的选择。Earl said his organization – Food Allergy Research and Education – has received a number of complaints from people who said they got sick by eating formerly “safe” products. Ruchi Gupta is a children's doctor at Northwestern University. She is director of the Center for Food Allergy and Asthma research there. Gupta called the FDA's decision “disappointing,” and noted that the food company and restaurant changes are permitted by law. However, she said she hoped the FDA would have “come out in a way to try to discourage” putting sesame in unusual products. Robert Califf leads the Food and Drug Administration. In a message posted online in 2023, he wrote about companies adding sesame to their foods. He called it “a practice with an outcome we do not support.” He said it does not break any rule but that it “limits options for consumers who are allergic to sesame.”厄尔说,他的组织——食物过敏研究和教育——收到了许多人们的投诉,他们说他们因为吃了以前“安全”的产品而生病了。鲁奇·古普塔 (Ruchi Gupta) 是西北大学的儿童医生。 她是那里食物过敏和哮喘研究中心的主任。 古普塔称 FDA 的决定“令人失望”,并指出食品公司和餐厅的改变是法律允许的。 然而,她表示,她希望 FDA 能够“采取某种方式阻止”在不寻常的产品中添加芝麻。罗伯特·卡利夫 (Robert Califf) 领导食品和药物管理局。 在 2023 年在线发布的一条消息中,他写到了一些公司在食品中添加芝麻的情况。 他称其为“我们不支持这种做法的结果”。 他表示,这并没有违反任何规则,但它“限制了对芝麻过敏的消费者的选择”。He also noted that consumers should “check the label every time you buy a food product – even if you have eaten it before and didn't have an allergic reaction.” The F.D.A. also said companies cannot use language like “may contain sesame” if the product does not contain it. Peter Lurie heads the CSPI. He said he hoped the FDA's recent statements would send a message to food companies. He said “it's on the companies to act responsibly,” if the FDA is not going to force them to make changes.他还指出,消费者应该“每次购买食品时检查标签——即使你以前吃过它并且没有过敏反应。”FDA 还表示,如果产品不含芝麻,公司就不能使用“可能含有芝麻”之类的语言。Peter Lurie 是 CSPI 的负责人。 他说,他希望 FDA 最近的声明能够向食品公司传达一个信息。 他说,如果 FDA 不强迫他们做出改变,“公司就有责任采取负责任的行动”。
Dementia affects 55 million people worldwide, and its most common form, Alzheimer's, accounts for about 70 percent of all cases.At the Alzheimer's Association International Conference, the largest congress advocating dementia science, held in Amsterdam this month, a pharmaceutical company disclosed details of its trials of a new drug: donanemab.The American company, Eli Lilly, expects the United States Food and Drug Administration (FDA) to decide by the end of 2023 whether to approve what it is calling a "breakthrough" drug.But is this medication the best way forward? Or does it just supply cash flow for the pharmaceutical industry?Leading dementia scientists Edo Richard and Craig Ritchie talk to Al Jazeera.Subscribe to our channel http://bit.ly/AJSubscribeFollow us on Twitter https://twitter.com/AJEnglishFind us on Facebook https://www.facebook.com/aljazeeraCheck our website: http://www.aljazeera.com/Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/@AljazeeraEnglish#Aljazeeraenglish#News
Skye Chilton of Real Mushrooms joins us to shed light on the ongoing Citizen Petition to the fDA to ensure accurate labeling of mushroom supplements. Many companies selling mycelium products are doing so with 'mushroom' labeling, which is a completely different part of the life cycle of a fungal organism. Skye analyzes the current petition to the United States Food and Drug Administration to require companies selling fungal products that are not actually mushrooms to accurately state so on their product labels.Please consider rating & reviewing the podcast wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.
Two cases concerning the FDA's approval of Mifepristone, Alliance for Hippocratic Medicine v. United States Food and Drug Administration (AHM v. FDA) and Washington v. United States Food and Drug Administration (WA v. FDA) have caused significant conversations concerning the FDA's approval processes, statutes of limitation for challenges to approvals, standing, administrative review, and judicial […]
Two cases concerning the FDA's approval of Mifepristone, Alliance for Hippocratic Medicine v. United States Food and Drug Administration (AHM v. FDA) and Washington v. United States Food and Drug Administration (WA v. FDA) have caused significant conversations concerning the FDA's approval processes, statutes of limitation for challenges to approvals, standing, administrative review, and judicial authority. The cases present interesting questions concerning the regulatory process, separation of powers, and the role of judges. In AHM v. FDA, a judge out of the Northern District of Texas blocked the FDA's approval of the drug, meaning it could no longer be distributed as an FDA-approved drug. The same day, in WA v. FDA, however, a separate district judge ruled the FDA was being overly restrictive and barred it from altering the regulatory status of Mifepristone in approximately a third of the country. Perhaps due to the drastic split between the courts, both cases have quickly ascended through the courts of appeals. In this program a panel of experts discuss these cases, their substance, and the possible ramifications of future decisions. Featuring: --Thomas Jipping, Senior Legal Fellow, Edwin Meese III Center for Legal and Judicial Studies, The Heritage Foundation--Adam Unikowsky, Partner, Jenner & Block LLP--[Moderator] Jennie Lichter, Deputy General Counsel, The Catholic University of America
The circumstances you're born in should not determine your worth. Shouldn't this be common sense? Apparently not. The recent case of the Alliance for Hippocratic Medicine Versus the United States Food and Drug Administration is the topic of conversation for our newest CareCast. CareCast is Care Net's Podcast on family, faith, and life and features your hosts Roland Warren, President and CEO of Care Net, and Vincent DiCaro, Care Net's Chief Outreach Officer. We invite you to sit down and listen to Roland and Vince as they dig deeper into the latest court case surrounding the abortion debate and more importantly, what's behind this quest for death, all on the latest episode of CareCast. Find the post and share at https://www.care-net.org/abundant-life-blog/alliance-for-hippocratic-medicine-v.-fda
May 9, 1960. The United States Food and Drug Administration revolutionizes society by approving the first birth control pill. Go to HistoryDaily.com for more history, daily.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Garza sits down with Paleface Swiss. We talk about they got into heavy music & became one of the heaviest bands to ever come out of their country. Putting schizophrenia awareness into beatdown & much more! https://www.palefaceswiss.com SPONSORS: Click this link to purchase from Sweetwater & help support the podcast: imp.i114863.net/rnrmVB TIME CODES: 00:00 - Playing Heavy Music 04:02 - Why Add “Swiss” to Name? 07:00 - Greenfield Festival 08:14 - Dan Kenny (Suicide Silence) Getting Paleface Swiss on Frankfurt, Germany Show 10:38 - How They Started Making Music Together By Stealing Each Other's Girlfriend 18:30 - Chapter 3: The Last Selection Writing Process 21:50 Paleface Swiss Has a Chill Vibe 22:54 - “666”, the Haunting Intro to Fear & Dagger, A Real Recording of a Schizophrenic Episode, Bringing Mental Health Awareness to Music 38:10 - Differences Between Switzerland & the United States (Food, Driving and Geography) 45:26 - First U.S. Tour Being Completely Sold Out (with Bodysnatcher, Angelmaker & Distant) 46:55 - Cultural & Societal Differences (continued) 51:54 - Eating Great Tacos in Exchange for Playing Beatdown Riffs 55:20 - What Got Them Into Heavy Music 59:30 - Illegally Downloading Music (& Other Files), Dangers of VR Porn
Food is a necessity for life. It should therefore surprise few that the federal government regulates the production and processing of food before it reaches our dinner tables. Labels indicating some meats are “USDA-Prime” or confirming that the product was inspected and approved as safe before delivery to the grocery store reflect this regulatory role.While labels may make the regulation apparent, which part of the administrative state handles that regulation can be less clear. Two agencies: the United States Department of Agriculture (USDA) and the Food and Drug Administration (FDA) -- part of the Department of Health and Human Services -- both have jurisdiction over the foods we consume. Which agency handles what is not always apparent. Recent illnesses and deaths involving baby formula and spinach -- both under the FDA's inspection jurisdiction -- have emphasized that regulatory structure can have life-or-death consequences. This has led some on both sides of the aisle to suggest a revamp of how we handle food safety regulation. One group contends the FDA should take the lead (Food being literally in the name); a second argues the USDA should run point (agriculture being the first step to food production), and a third group argues creating a separate agency entirely would be the best solution. The FDA itself has proposed an internal reorganization to emphasize its food safety mandate.This panel of FDA and USDA veterans whose service spanned multiple administrations will examine the questions (1) how safe is our food, (2) is a reorganization of the agencies that handle food safety necessary to achieve the maximum level of safety, and (3) how should such a reorganization look.Featuring:Dr. Mindy Brashears, Associate Vice President of Research, Endowed Chair, Professor & Director, International Center for Food Industry Excellence, Texas Tech University; Former Under Secretary of Agriculture for Food Safety, United States Department of AgricultureDr. Stephen Ostroff, Former Acting Commissioner and Former Deputy Commissioner for Foods and Veterinary Medicine, United States Food and Drug AdministrationFrank Yiannas, Former Deputy Commissioner for Food Policy and Response, United States Food and Drug Administration[Moderator] Hon. Stephen Alexander Vaden, Judge, United States Court of International Trade; Former General Counsel of the United States Department of AgricultureVisit our website - www.RegProject.org - to learn more, view all of our content, and connect with us on social media.
0:58 Labiotech.eu news2:37 Replay23:45 Azafaros39:39 GRO BiosciencesAs February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO Biosciences; Stefano Portolano, chief executive officer, Azafaros; and from Replay, Adrian Woolfson, executive chairman, president, and co-founder, and Lachlan MacKinnon, CEO and co-founder.Rare Disease DayTaking place on February 28 each year, the event raises awareness and looks to generate change for the 300 million people worldwide living with a rare disease, as well as their families and carers.This year, the day will be marked by more than 600 events in 106 countries.Replay and The University of Texas MD Anderson Cancer Center create SyenaReplay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs).Building on the intellectual property and technology from MD Anderson and Replay, Syena has the potential to create the next generation of cell therapy.AzafarosAzafaros is a clinical stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms, and a compound library from Leiden University. Its aim is to build a pipeline of disease-modifying therapeutics to offer patients and their families new treatment options. The company's lead clinical-staged program is AZ-3102, a small molecule, orally available, brain penetrant azasugar, with the potential to treat GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) and Niemann-Pick disease type C (NP-C). This week, the company announced it has been granted two Rare Pediatric Disease Designations (RPDD) by the United States Food and Drug Administration (FDA) for the treatment of GM1 and GM2 gangliosidoses, Orphan Medicinal Product Designation (OMPD) by the European Medicines Agency (EMA) for the treatment of GM2 gangliosidosis, and an Innovation Passport by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of GM1 and GM2 gangliosidoses.GRO BiosciencesGRO Biosciences is leveraging groundbreaking science to expand the amino acid alphabet and deliver on protein therapeutics. The U.S. company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The company's NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system.
Fladrafinil (CRL-40,941) belongs to a class of meds known as eugeroics. It was created in the '70s – approximately the same time that modafinil was developed as well – & was used to produce superb cognitive-ameliorating effects. Nonetheless, it's not authorized by the United States Food and Drug Administration (FDA). The chemical structure of Fladrafinil is similar to that of adrafinil, but there are several differences between them. Although it's not so famous, some people administer it to boost wakefulness, augment alertness, mental acuity & memory, heighten focus, & ultimately augment productivity. This guide https://modafinil.org/fladrafinil-review/ is all about Fladrafinil review. It covers everything you need to know about Fladrafinil. It discusses Fladrafinil ingredients, principal benefits, dosage, negative effects, & safety. It also reveals if Fladrafinil is similar to modafinil, and its comparison with Adrafinil & Flmodafinil. And where to shop it online. As mentioned in the guide, there are limited studies that support Fladrafinil safety & its cogency for both short- and long-term use. Most of the info shared in the guide about its benefits, dosage, and side effects are indeed anecdotal — they are based on user experiences. Certainly, the vast majority of “smart drug” enthusiasts who use it do so because they consider it to be more powerful than Adrafinil, armodafinil, & the famous modafinil (these are pharmaceuticals that are satisfactorily studied & widely used). The safest “smart drugs” are ultimately those approved by the FDA, have been considerably studied, & used by individuals globally. Certainly, modafinil & armodafinil provide better wakefulness-fostering & cognitive-augmenting benefits without inducing serious negative effects. Nonetheless, as revealed in the guide, if you're going to shop for them, accomplish that by using trusted pharmacies where you can be sure you'll get the real deal. Timestamp 00:28 What Is Fladrafinil? 00:57 How Does Fladrafinil Work? 01:13 About Fladrafinil Ingredients 01:26 Main Fladrafinil Benefits 02:18 Fladrafinil Dosage, Side Effects, and Safety 02:37 Side effects 02:43 Capsules vs Powder 03:07 Is Fladrafinil Like Modafinil? 03:23 Fladrafinil vs Adrafinil 03:39 Fladrafinil vs Flmodafinil 03:58 Where Can You Purchase Fladrafinil Online? 04:28 The Verdict: Fladrafinil Review
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S. District Court for the Northern District of Texas, Amarillo Division, against the United States Food and Drug Administration (FDA) on behalf of the Alliance of Hippocratic Medicine (AHM) and others. The suit challenges the FDA's 2000 decision to legalize mifepristone and misoprostol, two drugs often used in conjunction as chemical abortifacients. The petitioners argue that the legalization of these chemical abortion drugs undermines the FDA's legal obligation to protect the health, safety, and welfare of young girls and women. Further, the petitioners allege the FDA disregarded notable evidence that chemical abortion drugs are more likely to cause more harm and complications than a surgical abortion, and terminated the necessary safeguards for pregnant women and girls who undergo this controversial drug regimen. Finally, the petitioners contend that the FDA allowed these chemical abortion pills to be delivered via mail in violation of long-standing federal laws. This Litigation Update with Erik Baptist, a litigating attorney for ADF, will provide a current look at this case, what the facts are, how the case is going, and what the possible outcomes and ramifications thereof may be. Featuring:Erik Baptist, Senior Counsel, Alliance Defending Freedom[Moderator] Roger Klein, Faculty Fellow, Center for Law, Science & Innovation, Sandra Day O'Connor College of Law, Arizona State UniversityVisit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
In this episode host Lauren Walker, Program Director for the Hep C and Drug User Health Center of Excellence at CEI, speaks with special guests Dr. Sharon Stancliff and NYSDOH's Lisa Skill about the increasing health threat posed by Xylazine. Dr. Stancliff is Associate Medical Director of Harm Reduction in Healthcare and Medical Director of Harm Reduction in Healthcare, AIDS Institute, NYSDOH. She has been working with people who use drugs since 1990, and currently focuses on opioid overdose prevention. Lisa Skill is a Health Program Coordinator at the NYSDOH AIDS Institute Office of Drug User Health. Xylazine, often called “tranq” or “tranq dope” on the street, is being used to amplify and extend the effects of other drugs such as stimulants, opioids, and other sedatives. The drug was designed for veterinary use in animals as a sedative and muscle relaxant and is not approved for human consumption. Human use of Xylazine was first noted in Puerto Rico in the early 2000s, and has since spread across the U.S. into local drug supplies. In November 2022, the FDA issued a national warning to healthcare professionals to be cautious of the potential for xylazine inclusion in fentanyl, heroin and other illicit drug overdoses. This episode will describe xylazine trends and use over time, and provide clinicians with an understanding of the physiologic effects of xylazine intoxication. Dr. Sharon Stancliff and Lisa Skill will also share their clinical and harm reduction recommendations for xylazine intoxication, overdose and withdrawal. Related Content: NYSDOH Naloxone Availability without a prescription Safer Consumption Spaces - End Overdose NY Fiorentin TR, Logan BK. Analytical findings in used syringes from a syringe exchange program. Int J Drug Policy. 2022, 81:102770. doi: 10.1016/j.drugpo.2020.102770 Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022, 233:109380. doi: 10.1016/j.drugalcdep.2022.109380 Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019. Injury Prevention. 2021, 24:395-398. doi: 10.1136/injuryprev-2020-043968 Kariisa M, Patel P, Smith H, Bitting J. Notes from the field: Xylazine detection and involvement in drug overdose deaths – United States, 2019. MMWR Morb Mortal Wkly Rep. 2021, 70(37):1300-1302. doi: 10.15585/mmwr.mm7037a4 National Institute of Drug Abuse. Xylazine. Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, Martínez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. Forensic Sci Int. 2014, 240:1-8. doi: 10.1016/j.forsciint.2014.03.015 United States Department of Justice, Drug Enforcement Administration. Xylazine. November 2022. United States Food and Drug Administration. FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. November 2022. CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/
Welcome back to the Oh My Allergies! Podcast. Today's episode is for all our peeps that are allergic to sesame and/or are a parent/caregiver to someone who is allergic to sesame. We are talking all about the recent updates with the major allergen list due to the FASTER (Food Allergy Safety, Treatment, Education, and Research Act) today. If you didn't know, sesame is now a major allergen according to the United States Food and Drug Administration (FDA) as of January 1st of 2023. Although adding sesame to major allergen list is great for the allergy community, it has caused some backlash from the food industry. Valencia discusses what the Food Allergy Safety, Treatment, Education, and Research Act (FASTER) is, how this Act has affected those with sesame allergies, how restaurants and food manufacturers have reacted to the new requirements that come with sesame being a major allergen, why it's important now more than ever to read nutrition labels for all products (food, skincare, haircare, etc), and SO MUCH MORE. Tune in to learn more about how sesame can be found in a lot more foods and items than we think and also how to stay prepared in times like these as a person who's allergic to sesame. Allergy News Article - Tragedy as bride-to-be, 24, with dairy allergy dies four days after proposal on romantic South Africa holiday - 'after accidentally stirring tea with spoon that had come into contact with milk' - https://cutt.ly/R9hH2Pn Additional Resources: FARE Responds to Companies Intentionally Adding Sesame Flour as FASTER Act Goes Into Effect - https://cutt.ly/U9hH44K Sesame Added to FDA's Allergen Labeling Guidelines - https://cutt.ly/o9hH6M9 FDA Reminds Manufacturers Effective Date Sesame as a Major Allergen - https://cutt.ly/H9hJeQI Allergic Sesame Food Labels Now Must List Sesame Allergen - https://cutt.ly/v9hJu6O FASTER Act of 2021 - https://cutt.ly/S9hJONH Sesame Allergy and Food Labels - https://cutt.ly/n9hZI6Q Can Oats Have Gluten in Them? Podcast Episode (this where we discussed cross contact vs cross contamination) - https://cutt.ly/T9hLwyv 3 Ways You Can Support This Podcast: • Subscribe to the Oh My Allergies! Podcast • Rate and Review (just by tapping stars on Apple Podcast ★★★★★) • Share the Oh My Allergies! Podcast with everyone you know and don't know! JOIN THE OMA SQUAD: Podcast Instagram: https://cutt.ly/9JskuX5 Blog: https://cutt.ly/gJskpdw YouTube: https://cutt.ly/hAme9tN Follow Valencia on Instagram: https://cutt.ly/qAme3Rw Business Inquiries: ohmyallergies@gmail.com --- Send in a voice message: https://anchor.fm/oh-my-allergies/message
Videos : The Covid Redemption with Tim Robbins – #048 – Stay Free with Russell Brand MP calls for complete suspension of mRNA jab in extraordinary British Parliamentary speech Turmeric studied for its ability to seek out and destroy cancer stem cells, the source of all tumors Montclair State University, December 13, 202 Turmeric has gained immense popularity over the years not just for the unique flavor it adds to dishes like curries, but also for its various health benefits. One of its most promising therapeutic applications is as a natural remedy for cancer. Although the anticancer potential of turmeric isn't new, a recent study published in Cancer Letters further proved the importance of this golden spice in understanding and treating cancer. The team of American researchers evaluated the ability of curcumin, which is a polyphenol in turmeric, to target cancer stem cells that are assumed to be the primary cause of cancer tumor formation and malignancy. Unlike conventional cancer models used in previous studies, the cancer stem cell model suggests that only a small population of cancer cells drive the initiation, maintenance, and growth of tumors. These stem cells regularly undergo renewal and differentiation into other cancer cells, which no longer have the ability to regenerate themselves. Therefore, in this model, cancer stem cells that are not killed by treatments lead to the formation of more invasive and treatment-resistant tumors. In this study, the researchers found that curcumin is more effective in eradicating cancer since unlike conventional treatments, this polyphenol also targets cancer stem cells. It can do so through various mechanisms of action, which include the following. Regulation of cancer stem cell self-renewal pathway — There are different pathways involved in the self-renewal of cancer stem cells. These include the Wnt/beta-catenin, sonic hedgehog 89 (SHH), and Notch pathways. The researchers found that curcumin can directly or indirectly interfere with these pathways in 12 different cancer cell lines Modulation of microRNA — The body contains microRNAs, which are short RNA sequences that don't encode for anything. These microRNAs regulate more than 33 percent of protein-coding genes by targeting and binding to their corresponding messenger RNAs so that these won't be expressed. In this study, the authors observed that curcumin altered microRNA expression in cancer stem cells so that they can't produce everything that they need for tumor formation and growth. Direct anti-cancer activity — Curcumin selectively targets cancer cells and programs their death. When used in conjunction with conventional anticancer agents, this effect becomes more evident and the damage typically caused by chemotherapy is no longer observed. Overall, the results of this study show that for cancer treatments to be effective, they have to target and kill cancer stem cells just like turmeric does. Otherwise, these cancer stem cells will pave the way for the formation of more invasive and treatment-resistant tumors. (NEXT) Chiropractic spinal manipulation associated with reduction in low back surgery University Hospitals Cleveland Medical Center, December 19, 2022 A recent study from University Hospitals (UH) Connor Whole Health has found that adults who initially visit a chiropractor to receive spinal manipulation for low back pain caused by disc herniation or radiculopathy (i.e., sciatica) are less likely to undergo discectomy (i.e., disc surgery) over the subsequent two years. This study was recently published in the journal BMJ Open. In this retrospective cohort study, the authors selected adult patients, age 18 to 49, from a 101 million patient United States health records network (TriNetX, Cambridge, MA, U.S.). Patients with serious pathology or urgent indications for surgery were excluded from the study. Ultimately, the authors identified 5,785 patients who initially received chiropractic spinal manipulative therapy, and the same number of patients who received other forms of medical care for their low back pain. The authors used a statistical technique called propensity score matching to control for variables that could influence the likelihood that patients would undergo discectomy. In this process, they matched patients in both cohorts according to several such as age, sex, obesity, smoking, previous injections, and medications. The authors found that patients who initially received chiropractic spinal manipulation for their low back pain were significantly less likely to undergo lumbar discectomy through two years' follow-up. At one year follow-up, 1.5% of the patients in the chiropractic cohort had undergone discectomy, compared to 2.2% of patients in the cohort receiving other care At two years' follow-up, 1.9% of the patients in the chiropractic cohort had undergone discectomy, compared to 2.4% of patients in the cohort receiving other care This study represents the first study to examine whether chiropractic care is associated with a reduction in likelihood of discectomy. (NEXT) High-intensity exercise delays Parkinson's progression Northwestern Medicine and University of Denver, December 11, 2022 High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and decreases worsening of motor symptoms, according to a new phase 2, multi-site trial led by Northwestern Medicine and University of Denver scientists. This is the first time scientists have tested the effects of high-intensity exercise on patients with Parkinson's disease, the second most common neurodegenerative disorder and the most common movement disorder, affecting more than a million people in the United States. It previously had been thought high-intensity exercise was too physically stressful for individuals with Parkinson's disease. “If you have Parkinson's disease and you want to delay the progression of your symptoms, you should exercise three times a week with your heart rate between 80 to 85 percent maximum. Because medications for Parkinson's have adverse side effects and reduced effectiveness over time, new treatments are needed. The randomized clinical trial included 128 participants ages 40 to 80 years old from Northwestern University, Rush University Medical Center, the University of Colorado and the University of Pittsburgh. Participants enrolled in the Study in Parkinson Disease of Exercise (SPARX) were at an early stage of the disease and not taking Parkinson's medication, ensuring the results of the study were related to the exercise and not affected by medication. “The earlier in the disease you intervene, the more likely it is you can prevent the progression of the disease,” Corcos said. “We delayed worsening of symptoms for six months; whether we can prevent progression any longer than six months will require further study.” Scientists examined the safety and effects of exercise three times weekly for six months at high intensity, 80 to 85 percent of maximum heart rate, and moderate intensity, 60 to 65 percent of maximum heart rate. They compared the results to a control group who did not exercise. After six months, participants were rated by clinicians on a Parkinson's disease scale ranging from 0 to 108. The higher the number, the more severe the symptoms. Participants in the study had a score of about 20 before exercise. Those in the high intensity group stayed at 20. The group with moderate exercise got worse by 1.5 points. The group that did not exercise worsened by three points. Three points out of a score of 20 points is a 15 percent change in the primary signs of the disease and considered clinically important to patients. It makes a difference in their quality of life. (NEXT) Meditation adapts the brain to respond better to feedback University of Surrey UK, December 11, 2022 In a study in the Journal of Cognitive, Affective & Behavioral Neuroscience researchers from the University of Surrey have discovered a link between meditation and how individuals respond to feedback. Participants in the study, a mixture of experienced, novice and non-meditators, were trained to select images associated with a reward. Each pair of images had varying probabilities of a reward e.g. images that result in a reward 80 per cent of the time versus those that result in a reward 20 per cent of the time. Participants eventually learnt to select the pairing with the higher outcome. Researchers found that participants who meditated were more successful in selecting high-probability pairings indicating a tendency to learn from positive outcomes, compared to non – meditators who learned the pattern via low-probability pairings suggesting a tendency to learn from negative outcomes. During the study participants were connected to an EEG, a non-invasive method that records electrical patterns in the brain. Results from the EEG found that while all three groups responded similarly to positive feedback, the neurological response to negative feedback was highest in the non-meditation group, followed by the novice group and then by the experienced meditation group. These results indicate that the brains of meditators are less affected by negative feedback, and that this may be a result of altered dopamine levels caused by meditation. Paul Knytl, lead author and PhD candidate in psychology at the University of Surrey, said: “Humans have been meditating for over 2000 years, but the neural mechanisms of this practice are still relatively unknown. These findings demonstrate that, on a deep level, meditators respond to feedback in a more even-handed way than non-meditators, which may help to explain some of the psychological benefits they experience from the practice.” (NEXT) Caution to pregnant women on red meat diabetes link University of Adelaide (Australia) December 12, 2022 Pregnant women and women planning to become pregnant can make use of the holiday season to adjust their diets and reduce the risk of gestational diabetes, according to researchers at the University of Adelaide's Robinson Institute. The recommendation comes at a time when there is increasing evidence to suggest that red meat is linked with a higher rate of gestational diabetes in pregnant women, which poses risks to the health of both the mother and the baby. In a commentary published in the jjournal Evidence-Based Nursing, author Philippa Middleton says the latest international research shows that women who eat a lot of red and processed meats even before they become pregnant have a significant risk of developing gestational diabetes. “There have been several reports linking red meat with increased risk of type 2 diabetes, and now the work of a number of research teams worldwide is showing this link for diabetes during pregnancy,” says Ms Middleton, who is one of the Robinson Institute's research leaders. “While this news is alarming, there are also some positives. The latest research from the United States has shown that eating fish and poultry does not increase the risk of gestational diabetes, and consuming more vegetable and non-meat protein is associated with a reduction in risk. “For example, just over half a serving of nuts per day can reduce the risk of gestational diabetes by 40%.” “Based on current evidence, pregnant women or women planning to become pregnant should consider eating more vegetable protein, and nuts, and replacing some red meat with fish and poultry. (NEXT) Treatment for lupus may depend on restoring proteins in patients' blood Singapore General Hospital, December 19, 2022 Restoring protein balance in the blood may be key to developing an effective treatment for lupus. The incurable autoimmune disease reportedly affects about 100 in every 100,000 people worldwide, and disproportionally affects women between 15 and 45 years-old and Asians. Lupus causes the body's immune system to attack itself, which can inflame several vital organs like the kidneys, brain, heart, and lungs. The aggressive nature of the disease is what makes it life-threatening for many who have it, especially since current treatments don't help that much. “We are excited about the possibility of a new treatment option for lupus as 30 to 60 percent of patients do not respond to conventional medications despite aggressive regimens. In the past 65 years, only three drugs for lupus have been approved by the United States Food and Drug Administration but these drugs have modest efficacy. There is therefore a real and urgent need for better therapies, particularly for the more severe spectrum of lupus that we see in Asia,” says senior author Andrea Low, the Head and Senior Consultant in the Department of Rheumatology & Immunology at Singapore General Hospital (SGH), in a media release. To reach their findings, Low and her team studied CXCL5, a protein that helps to regulate the immune system through neutrophils, which are a type of white blood cell. They revealed that lupus patients had considerably lower levels of the protein in their blood compared to healthy people, thus suggesting that it may have a connection to the disease. They also discovered that mice with severe lupus injected weekly with CXCL5 displayed restored protein balance. Moreover, their survival outcomes increased from 25 percent to over 75 percent after 10 weeks. Not only did the injections reduce mortality risk, but they didn't cause any adverse side-effects, study authors report. “Our study has shown CXCL5 to be safe. There was no liver or kidney toxicity or cancer inducing effects. Major components of the immune system were also not compromised,” reports principal investigator Dr Fan Xiubo, Senior Research Fellow, Department of Clinical Translational Research, SGH. The entire team is hopeful that they can continue to build on their research to better the lives of patient's suffering from this debilitating disease. “To be in the forefront of medicine means we have to constantly further our understanding of diseases and offer patients better treatment options through rigorous scientific research. I'm heartened that the team has shed new light on lupus and the possibility of a more efficacious therapy for patients some years down the road,” says Professor Fong Kok Yong, Deputy Group CEO (Medical and Clinical Services), SingHealth, and Senior Consultant, Department Rheumatology & Immunology, SGH
Key Takeaways: There are TEN TIMES the number of bacteria in our body than our own cells and the majority of them are found within our digestive system. The gastrointestinal system contains 90% of the body's happy hormone, serotonin. Most importantly, approximately 70% of our immune system is housed in our gut! Episode Summary: The gut, or gastrointestinal system, is truly a gateway to good health. The gut microbiome is an ecosystem of organisms including bacteria, yeasts, fungi, viruses, and protozoan throughout the digestive tract. Far beyond just digestive health, the following organ systems are also closely related to gut health: Immune system Endocrine system Nervous system Circulatory system Integumentary system Respiratory system Reproductive system "The food pyramid might be out of date and confusing to most." Many find they have refigured their food pyramid for convenience, without understanding the harm they are doing to their bodies. For many, it consists of: Grain at the base; Dairy in the middle; . . . and Sugar at the top. "To be frank, none of these foods have any business being part of your diet at all." In this YOUNGER podcast episode, I will help you wake up to how the majority of our diets are now packaged meals with paragraph-long ingredient lists and labels we can't understand due to convenience. We are all busy and cooking takes time, but if this is your situation, just know you may not be eating real food at all! Here are a couple of alarming facts you should know: The United States Food and Drug Administration (FDA) has approved approximately 3,000 different food additives, preservatives, and colorings without adequate research on safety! The average person ingests over 150 pounds of additives each year! The impact based on the fact that such chemicals that have been allowed into our lives is incomprehensible and might be considered experimental. As we become more and more aware of the consequences of this fake-food lifestyle we begin to recognize it is simply unacceptable! The disturbing facts above point to only a few key factors in the leaky gut epidemic, but I do find they are the bigger ones! Here are a couple of alarming facts: The United States Food and Drug Administration (FDA) has approved approximately 3,000 different food additives, preservatives, and colorings without adequate research on safety! The average person ingests over 150 pounds of additives each year! The impact based on the fact that such chemicals that have been allowed into our lives is incomprehensible and might be considered experimental. As we become more and more aware of the consequences of this fake-food lifestyle we begin to recognize it is simply unacceptable! “This information is only one factor in the leaky gut epidemic, but I do find it one of the bigger ones!” Guest Bio: Dr. Robyn Benson is a Doctor of Oriental Medicine (DOM) who brings an innovative and game-changing approach to today's health care. Robyn offers the most advanced and cutting-edge therapies, procedures, and products designed to renew, restore, and revive health called A.R.T.: Amplified Regenerative Therapies. Dr. Benson, author, speaker, and self-care and Regenerative Medicine* expert, is known by many to be THE health detective with life-changing solutions! She has been the owner and founder of the Santa Fe Soul Center for Optimal Health (now Regenerative Medicine) for close to two decades. For almost 30 years, Dr. Benson has applied her considerable knowledge of acupuncture, platelet-rich plasma (PRP) therapy, herbs, IV therapies, and her love for healthy travel to help patients resolve acute and chronic health challenges and to achieve optimal and sustainable health without the use of pharmaceuticals or surgery. Resources for a Younger Lifestyle: A resource link for all my YOUNGER episodes: https://robynbenson.com/podcasts/ Demystifying Detox (episode # 86) by Dr. Robyn Benson Optimize You Mitochondrial Health and Create Bio Resilience (episode #25) with Shawn Wells Your Gut, Your Health Your Wealth (episode #20) with Dr. Vincent Pedre The Truth About Parasites in America (episode #11) with Dr. Glenn Wilcox Your Health, Your Gut, Your Microbiome, They're All Connected (episode #5) with Ken Brown, MD Your Food, Your Health, Your Wealth (episode #2) with Terry Wahls, MD Quotes: “Gut health doesn't stop at digestion. The health of our gut affects nearly every system in our body!" "Gluten allergies, sensitivities, and intolerances are becoming increasingly more common, “gluten-free” has become the “buzz word” within the health community, and people are finally beginning to understand how dangerous gluten can be for their health." "Much like the additives and preservatives flooding our food supply, pesticides are also a big part of what's on our plates that even a strongest gut can't seem to process and eliminate without help."
2:22 Labiotech.eu news4:53 TAU Systems21:54 Bone Health Technologies 33:26 Immutep44:36 JLLThis week, we have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidateImmutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of first line non-small cell lung cancer (NSCLC).Efti is the company's first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage both the innate and adaptive immune system to target solid tumors.The designation has been granted for the development of efti in combination with pembrolizumab in first line treatment of stage IIIB/IV NSCLC patients expressing PD-L1 tumor proportion score greater than or equal to 1%, not amenable to EGFR/ALK based therapy. The designation is based on the TACTI-002/KEYNOTE-798 phase II clinical data in first line NSCLC for PD-L1 all-comers.This represents the second fast track designation for efti, following the same designation in April 2021 for efti in combination with pembrolizumab in first line treatment of recurrent or metastatic head and neck squamous cell carcinoma. TAU Systems to build new generation of compact particle accelerators after $15M investmentTAU Systems has raised $15 million in seed investment to bring particle accelerators to a multitude of users by harnessing the latest laser technology to make electrons surf on three-dimensional plasma waves and accelerate them to ultra-high energies.The news is significant as, until now, high-energy particle accelerators have been limited to countries and governmental organizations. Due to their huge size and high cost, access for engineers and biotech professionals is severely limited. The laser-driven particle accelerators and X-ray free-electron lasers (XFEL) developed by TAU Systems will give access to a world of ultra-small objects evolving ultra-fast under ultra-powerful conditions – TAU's team calls it the Ultraverse.TAU Systems said it will offer beamtime, data acquisition and analysis as a full-service supplier as well as complete laser-driven accelerators and XFEL systems for sale, to, for example, pharma and biotech, battery and solar technology, and other material-science driven markets. Bone Health Technologies at ASBMR 2022The American Society for Bone and Mineral Research (ASBMR) annual meeting was held recently in Texas.The ASBMR is a professional, scientific and medical society established to bring together clinical and experimental scientists who are involved in the study of bone and mineral metabolism.One of the companies attending was Bone Health Technologies, a San Francisco-based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures. The company has created OsteoBoost, the first vibration belt specifically designed to treat osteopenia and prevent osteoporosis.Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis). SponsorInter
Pyrlcasts, brought to you by Pyrls.com! We take a closer look at interesting and relevant clinical topics related to pharmacotherapy. Want to learn more clinical pearls? Boost your clinical confidence? Visit and sign-up for an account at pyrls.com to get over 10 high-quality charts absolutely FREE! Episode References: Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. J Alzheimers Dis. 2012;32(4):793-887. doi:10.3233/JAD-2012-121186 Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992;17(2):139-170. doi:10.1016/0165-0173(92)90012-b Institute of Medicine (US) Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academies Press (US); 2001. 2, Pharmacology of Caffeine. Available from: https://www.ncbi.nlm.nih.gov/books/NBK223808/ Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol. 2003;285(4):F590-F599. Faudone G, Arifi S, Merk D. The Medicinal Chemistry of Caffeine. J Med Chem. 2021;64(11):7156-7178. doi:10.1021/acs.jmedchem.1c00261oi:10.1152/ajprenal.00051.2003 Gessi S, Merighi S, Fazzi D, Stefanelli A, Varani K, Borea PA. Adenosine receptor targeting in health and disease. Expert Opin Investig Drugs. 2011;20(12):1591-1609. doi:10.1517/13543784.2011.627853 Spilling the Beans: How Much Caffeine is Too Much? United States Food and Drug Administration. Updated Dec 12, 2018. Accessed Aug 4, 2022. https://www.fda.gov/consumers/consumer-updates/spilling-beans-how-much-caffeine-too-much#:~:text=For%20healthy%20adults%2C%20the%20FDA,it%20(break%20it%20down). Brain Basics: Understanding Sleep. National Institute of Neurological Disorders and Stroke. Updated July 25, 2022. Accessed Aug 4, 2022. https://www.ninds.nih.gov/health-information/patient-caregiver-education/brain-basics-understanding-sleep
2:15 Labiotech.eu news5:12 Phase Genomics16:44 IRB Barcelona29:37 Ilya Pharma43:00 Krystal Biotech53:54 JLLOur guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO of Phase Genomics.We also have a new weekly addition, as JLL will be joining us with a look at financial news. This week, we're joined by Robert Coughlin, JLL managing director and New England Life Science Practice Group lead.Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instabilityCRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types of cancer and HIV.Scientists at IRB Barcelona, led by ICREA researcher Fran Supek, have now reported that, depending on the targeted spot of the human genome, CRISPR gene editing can give rise to cell toxicity and genomic instability. Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.These are: one in India, and continuation patents in China, Australia and the U.S. This means the company's method for using modified bacteria for treatment of both mucosal and cutaneous wounds in humans and animals has patent protection in all major markets.Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.Krystal Biotech gets green light for cystic fibrosis trialU.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application.The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the respiratory cells in the lungs. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has the potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation.Phase Genomics using ProxiMeta for phage-bacteria interactionsPhase Genomics, Inc., a developer of proximity ligation-based genomic solutions, recently received $5.5M in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. With the new funding, Phase Genomics will leverage its phage-bacteria interactome repository to power the development of an AI-driven predictive engine for therapeutic phage discovery.The new financing will allow the company to harness its proximity-guided metagenomics platform, ProxiMeta, to develop the world's largest atlas of phage-bacteria interactions and use machine learning tools to identify phages that can be used in therapeutic settings such as C. difficile infections, ulcerative colitis, and Crohn's disease.
Dr. Lori Provencher discusses the clinical trial and FDA approval of the CustomFlex Artificial Iris with Dr. Michael Snyder, author of “Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris.” Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris. Ayres, Brandon D. et al. Ophthalmology, Volume 129, Issue 6, 614 – 625.
Do you even vape, bro? Well if the United States Food and Drug Administration has its way, that answer might soon be a hard "no." Last month, the FDA went after Juul, the reigning champ of the e-cigarette industry, and effectively banned the selling of all Juul products in the US. Of course, Juul fought back, and a judge stayed the order. Now, as Juul fights for its life, the rest of the multibillion dollar market of nicotine-dispensing tech has billowed in to fill the space. This week on Gadget Lab, WIRED senior writer Arielle Pardes joins us to talk about Juul's battle with the FDA and what it means for vaping and nicotine products as a whole. Show Notes Read Arielle's story about the battle between Juul and the FDA. Follow all of WIRED's coverage of Juul and vaping. Read the GQ profile on actor Jeremy Allen White. Recommendations Arielle recommends Nixta licor de elote, if you're of booze drinking age. Lauren recommends the show The Bear on Hulu. Mike recommends The Copenhagen Trilogy by Tove Ditlevsen. Arielle Pardes can be found on Twitter @pardesoteric. Lauren Goode is @LaurenGoode. Michael Calore is @snackfight. Bling the main hotline at @GadgetLab. The show is produced by Boone Ashworth (@booneashworth). Our theme music is by Solar Keys. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Blossom Your Awesome Episode #55 Creating Connection With David Woods BartleyDavid Woods Bartley helps people journey from Mental Wellness to Mental Wellness. David has seen his fair share of successes and setbacks; from directing a nationally recognized nonprofit to battling a life-threatening mental illness. But over the last seven years, David has successfully navigated from the isolation of mental “hellness” to the inclusive space of mental wellness.David is a member of the National Alliance on Mental Illness, the International Association for Youth Mental Health, the National Storytelling Network's Healing Story Alliance, and Active Minds. David holds certifications in Mental Health First Aid for Adults and Youth, SafeTALK (Suicide Awareness for Everyone), and is a national trainer for the groundbreaking suicide prevention technique known as QPR (Question, Persuade and Refer).David has been invited to speak to domestic and international audiences, giving keynote speeches and leading workshops on a variety of aspects of mental health, including suicide awareness and prevention, the power of connection to create hope, and the use of language as a tool for healing. In addition to giving a TEDx talk in the fall of 2018, David has been invited to present to organizations such as the United States Food and Drug Administration, the Army Corps of Engineers, Novartis, Takeda Pharmaceuticals, Lyft, Sutter Health, Vision Service Plan, the University of Connecticut, the California Northstate School of Medicine, UC Davis, Sacramento State, William Jessup University, along with various faith denominations, law enforcement agencies and community organizations at the local, state and national level.David's goal for each speech and workshop is the same: to shed light on the issue of mental illness, teach people how to leverage curiosity to overcome our fears and use connection to create hope. Topics We Discuss:Mental Illness and Mental HealthSuicide awareness and preventionDepression and other related conditionsThe effect of stigma and ways to change perceptionsHow to create connection and hopeAdvice for those sufferingPractical tips to help loved ones who are sufferingThe power of connection to create hope, and the use of hope to save livesUsing storytelling to aid in the healing and help10 Interview Questions You Can Ask MeWhat led up to you wanting to kill yourself on August 31, 2011?What did your life look like at the time, and did anyone know you were suffering?How meaningful is it now to be doing such purposeful work?You are saving lives. How does that feel?What does it feel like to live with a mental illness, and how it impacts daily living?What are some of the causes of mental illness?What do you see as the biggest obstacles for people to experience true mental health? CONNECT WITH DAVIDWebsitehttps://www.davidwoodsbartley.com/LinkedIn URLhttps://www.linkedin.com/in/david-woods-bartley-96325512/Facebook URLhttps://www.facebook.com/david.w.bartley.5YouTube URLhttps://www.youtube.com/channel/UCFEo9TcsIGCcQgBiihgXdrg/videosTo see more of my work go to Blossom Your Awesome. Or you can see some of my other work at suesblues.com Or follow me on instagram where I post fairly regularly and ask an inquisitive question or two weekly in hopes of getting you thinking about your life and going deeper with it. My Instagra
Welcome back, to another clip from Doc's Thought of the Day. Today Doc discusses the fact several dozen Food Processing plants have been destroyed around the United States and Canada.Website - https://www.thatsonpoint.infoFollow Us On;Bitchute-https://www.bitchute.com/channel/8SXcz1rqDyu7/YouTube-https://www.youtube.com/channel/UCRNHroldv9kuaatarS7uclAMinds-https://www.minds.com/thatsonpoint/ToP Clips: https://www.youtube.com/channel/UCn_fZ4JhHN05YLijsdmkYSQ/Paler:https://parler.com/profile/DocComeauSupport Us On;Subscribe Star-https://www.subscribestar.com/that-s-on-pointPatreon-https://www.patreon.com/ThatsOnPoint?fan_landing=tru
Welcome back, to another clip from Doc's Thought of the Day. Today Doc discusses the fact several dozen Food Processing plants have been destroyed around the United States and Canada.Website - https://www.thatsonpoint.infoFollow Us On;Bitchute-https://www.bitchute.com/channel/8SXcz1rqDyu7/YouTube-https://www.youtube.com/channel/UCRNHroldv9kuaatarS7uclAMinds-https://www.minds.com/thatsonpoint/ToP Clips: https://www.youtube.com/channel/UCn_fZ4JhHN05YLijsdmkYSQ/Paler:https://parler.com/profile/DocComeauSupport Us On;Subscribe Star-https://www.subscribestar.com/that-s-on-pointPatreon-https://www.patreon.com/ThatsOnPoint?fan_landing=tru
Welcome back, to Doc's Thought of the Day. Today Doc discusses the fact around two dozen food processing facilities have been destroyed in North America over the last few months.Website - https://www.thatsonpoint.infoFollow Us On;Bitchute-https://www.bitchute.com/channel/8SXcz1rqDyu7/YouTube-https://www.youtube.com/channel/UCRNHroldv9kuaatarS7uclAMinds-https://www.minds.com/thatsonpoint/ToP Clips: https://www.youtube.com/channel/UCn_fZ4JhHN05YLijsdmkYSQ/Paler:https://parler.com/profile/DocComeauSupport Us On;Subscribe Star-https://www.subscribestar.com/that-s-on-pointPatreon-https://www.patreon.com/ThatsOnPoint?fan_landing=tru
Welcome back, to Doc's Thought of the Day. Today Doc discusses the fact around two dozen food processing facilities have been destroyed in North America over the last few months.Website - https://www.thatsonpoint.infoFollow Us On;Bitchute-https://www.bitchute.com/channel/8SXcz1rqDyu7/YouTube-https://www.youtube.com/channel/UCRNHroldv9kuaatarS7uclAMinds-https://www.minds.com/thatsonpoint/ToP Clips: https://www.youtube.com/channel/UCn_fZ4JhHN05YLijsdmkYSQ/Paler:https://parler.com/profile/DocComeauSupport Us On;Subscribe Star-https://www.subscribestar.com/that-s-on-pointPatreon-https://www.patreon.com/ThatsOnPoint?fan_landing=tru
Antioxidants may get all the headlines, but magnesium may just be your health MVP. Learn more about the benefits of this mineral. Did you know that Magnesium is the fourth most abundant mineral in the human body? According to the National Institute of Health… Magnesium is a nutrient that the body needs to stay healthy. Magnesium is important for many processes in the body, including regulating muscle and nerve function, blood sugar levels, and blood pressure and making protein, bone, and DNA. Let's dive a bit deeper into just how important Magnesium is to our health… It acts as a cofactor for more than 300 enzymes, regulating a number of fundamental functions such as muscle contraction, neuromuscular conduction, glycemic control, myocardial contraction, and blood pressure. Magnesium also plays a vital role in energy production, active transmembrane transport for other ions (ATP), synthesis of nuclear materials, and bone development. Important to note – magnesium deficiency has been associated with a wide range of diseases. Magnesium and Nutrition According to the United States Food and Nutrition Board, recommended daily allowance for magnesium is 420 mg for adult males and 320 mg for adult females, respectively. Approximately 10% of the daily magnesium requirement is derived from water. Green vegetables, nuts, seeds, and unprocessed cereals are rich sources of magnesium. Also, some magnesium is available in fruits, fish, meat, and milk products. The majority of the population in the Western countries consume less than the recommended amount of magnesium, contributed by the consumption of processed foods, demineralized water, and agricultural practices using soil deficient in magnesium for growing food. Many studies have demonstrated beneficial effects of magnesium supplementation. Chronic Diseases Associated with Magnesium Deficiency type 2 diabetes & metabolic syndrome Studies suggest that about 48% of people with type 2 diabetes have low levels of magnesium in their blood. This can impair insulin's ability to keep blood sugar levels under control One study which followed more than 4,000 people for 20 years found that those with the highest magnesium intake were 47% less likely to develop diabetes. hypertension Magnesium helps lower blood pressure in people with elevated levels but does not seem to have the same effect in those with normal levels. cardiovascular disease (e.g., stroke, atherosclerotic vascular disease, sudden cardiac death) osteoporosis migraine headache asthma colon cancer Alzheimer's disease attention deficit hyperactivity disorder (ADHD) Other Areas of Health Where Magnesium Helps May boost exercise performance Magnesium helps move blood sugar into your muscles and dispose of lactate, which can build up during exercise and cause fatigue Studies have shown that supplementing with it can boost exercise performance for athletes, the elderly and people with chronic disease In a study, athletes who supplemented with magnesium for four weeks had faster running, cycling and swimming times during a triathlon. They also experienced reductions in insulin and stress hormone levels Magnesium supplements have been shown to enhance exercise performance in several studies, but research results are mixed. Magnesium Fights Depression Magnesium plays a critical role in brain function and mood, and low levels are linked to an increased risk of depression One analysis in over 8,800 people found that people under the age of 65 with the lowest magnesium intake had a 22% greater risk of depression. Some experts believe the low magnesium content of modern food may cause many cases of depression and mental illness; however, others emphasize the need for more research in this area. Nonetheless, supplementing with this mineral may help reduce symptoms of depression — and in some cases, the results can be dramatic. In a randomized controlled trial in depressed older adults, 450 mg of magnesium daily improved mood as effectively as an antidepressant drug. Anti-Inflammatory Benefits Low magnesium intake is linked to chronic inflammation (elevated C-reactive protein), which is one of the drivers of aging, obesity and chronic disease. Magnesium supplements can reduce CRP and other markers of inflammation in older adults, overweight people and those with prediabetes. In the same way, high-magnesium foods — such as fatty fish and dark chocolate — can reduce inflammation. Magnesium Improves PMS Symptoms Premenstrual syndrome (PMS) is one of the most common disorders among women of childbearing age. Its symptoms include water retention, abdominal cramps, tiredness and irritability. Interestingly, magnesium has been shown to improve mood, reduce water retention and other symptoms in women with PMS Magnesium Is Safe and Widely Available Magnesium is absolutely essential for good health. The recommended daily intake is 400–420 mg per day for men and 310–320 mg per day for women. You can get it from both food and supplements. Food Sources The following foods are good to excellent sources of magnesium: Pumpkin seeds: 46% of the RDI in a quarter cup (16 grams) Spinach, boiled: 39% of the RDI in a cup (180 grams) Swiss chard, boiled: 38% of the RDI in a cup (175 grams) Dark chocolate (70–85% cocoa): 33% of the RDI in 3.5 ounces (100 grams) Black beans: 30% of the RDI in a cup (172 grams) Quinoa, cooked: 33% of the RDI the in a cup (185 grams) Halibut: 27% of the RDI in 3.5 ounces (100 grams) Almonds: 25% of the RDI in a quarter cup (24 grams) Cashews: 25% of the RDI in a quarter cup (30 grams) Mackerel: 19% of the RDI in 3.5 ounces (100 grams) Avocado: 15% of the RDI in one medium avocado (200 grams) Salmon: 9% of the RDI in 3.5 ounces (100 grams) Supplements If you have a medical condition, check with your doctor before taking magnesium supplements. Though these are generally well-tolerated, they may not be safe for people who take certain diuretics, heart medications or antibiotics. Organixx's Magnesium 7: MAGNESIUM CHELATE This form of magnesium is especially important for muscle building, recovery, and health. [17] MAGNESIUM CITRATE Helps with the effects of obesity. In fact, one study found that this form helped arterial stiffness in healthy overweight individuals. MAGNESIUM BISGLYCINATE Often used to treat symptoms of excess stomach acid, such as stomach upset, heartburn, and acid indigestion. MAGNESIUM MALATE Some believe this to be the most bioavailable form of magnesium. It's found naturally in fruits, giving them a “tart taste.” Magnesium Malate can help with migraines, chronic pain, and depression. MAGNESIUM ASPARTATE This form helps the connection between your brain and muscles, your cardiac rhythms, and the overall acid-alkaline balance in your body. It also can support an elevated mood. It is absolutely essential in the metabolism of macronutrients, as well as the utilization of other minerals, B-complex vitamins, vitamin C and vitamin E. MAGNESIUM TAURATE This is the form of magnesium best for your heart. One study noted: “The complex magnesium taurate may thus have considerable potential as a vascular-protective nutritional supplement.” MAGNESIUM OROTATE While also helpful for the heart, magnesium orotate is believed to be the best form for metabolic improvements. This makes it a favorite for athletes seeking enhanced recovery, energy and performance. Resources: Organixx Magnesium 7 - Complete Full-Spectrum Daily Magnesium Supplement Magnesium and Human Health: Perspectives and Research Directions Volume 2018 |Article ID 9041694 J. Bertinato, C. Wu Xiao, W. M. Ratnayake et al., “Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men,” Food & Nutrition Research, vol. 59, no. 1, article 25974, 2015. U. Grober, J. Schmidt, and K. Kisters, “Magnesium in prevention and therapy,” Nutrients, vol. 7, no. 9, pp. 8199–8226, 2015. J. H. F. de Baaij, J. G. J. Hoenderop, and R. J. M. Bindels, “Magnesium in man: implications for health and disease,” Physiological Reviews, vol. 95, no. 1, pp. 1–46, 2015. Reported Dietary Intake, Disparity between the Reported Consumption and the Level Needed for Adequacy and Food Sources of Calcium, Phosphorus, Magnesium and Vitamin D in the Spanish Population: Findings from the ANIBES Study Suboptimal magnesium status in the United States: are the health consequences underestimated? Magnesium in Prevention and Therapy Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients The effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients Magnesium enhances exercise performance via increasing glucose availability in the blood, muscle, and brain during exercise Magnesium in depression Magnesium intake and depression in adults Rapid recovery from major depression using magnesium treatment Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures A pilot study on the effects of magnesium supplementation with high and low habitual dietary magnesium intake on resting and recovery from aerobic and resistance exercise and systolic blood pressure The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial Nutrition by Food Search: Magnesium - Fact Sheet for Health Professionals Chelated Magnesium Effects of magnesium citrate, magnesium oxide and magnesium sulfate supplementation on arterial stiffness in healthy overweight individuals: a study protocol for a randomized controlled trial Magnesium Glycinate A pilot study of magnesium aspartate hydrochloride (Magnesiocard®) as a mood stabilizer for rapid cycling bipolar affective disorder patients Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate Metabolic supplementation with orotic acid and magnesium orotate Magnesium enhances exercise performance via increasing glucose availability in the blood, muscle, and brain during exercise Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial 7 Serious Health Issues Linked to Magnesium Deficiency (+ How to Tell If You're Magnesium Deficient) What You Need to Know About Magnesium for Depression and Anxiety Magnesium for Better Sleep: Does it Help & What Type Do You Need?
Antioxidants may get all the headlines, but magnesium may just be your health MVP. Learn more about the benefits of this mineral. Did you know that Magnesium is the fourth most abundant mineral in the human body? According to the National Institute of Health… Magnesium is a nutrient that the body needs to stay healthy. Magnesium is important for many processes in the body, including regulating muscle and nerve function, blood sugar levels, and blood pressure and making protein, bone, and DNA. Let's dive a bit deeper into just how important Magnesium is to our health… It acts as a cofactor for more than 300 enzymes, regulating a number of fundamental functions such as muscle contraction, neuromuscular conduction, glycemic control, myocardial contraction, and blood pressure. Magnesium also plays a vital role in energy production, active transmembrane transport for other ions (ATP), synthesis of nuclear materials, and bone development. Important to note – magnesium deficiency has been associated with a wide range of diseases. Magnesium and Nutrition According to the United States Food and Nutrition Board, recommended daily allowance for magnesium is 420 mg for adult males and 320 mg for adult females, respectively. Approximately 10% of the daily magnesium requirement is derived from water. Green vegetables, nuts, seeds, and unprocessed cereals are rich sources of magnesium. Also, some magnesium is available in fruits, fish, meat, and milk products. The majority of the population in the Western countries consume less than the recommended amount of magnesium, contributed by the consumption of processed foods, demineralized water, and agricultural practices using soil deficient in magnesium for growing food. Many studies have demonstrated beneficial effects of magnesium supplementation. Chronic Diseases Associated with Magnesium Deficiency type 2 diabetes & metabolic syndrome Studies suggest that about 48% of people with type 2 diabetes have low levels of magnesium in their blood. This can impair insulin's ability to keep blood sugar levels under control One study which followed more than 4,000 people for 20 years found that those with the highest magnesium intake were 47% less likely to develop diabetes. hypertension Magnesium helps lower blood pressure in people with elevated levels but does not seem to have the same effect in those with normal levels. cardiovascular disease (e.g., stroke, atherosclerotic vascular disease, sudden cardiac death) osteoporosis migraine headache asthma colon cancer Alzheimer's disease attention deficit hyperactivity disorder (ADHD) Other Areas of Health Where Magnesium Helps May boost exercise performance Magnesium helps move blood sugar into your muscles and dispose of lactate, which can build up during exercise and cause fatigue Studies have shown that supplementing with it can boost exercise performance for athletes, the elderly and people with chronic disease In a study, athletes who supplemented with magnesium for four weeks had faster running, cycling and swimming times during a triathlon. They also experienced reductions in insulin and stress hormone levels Magnesium supplements have been shown to enhance exercise performance in several studies, but research results are mixed. Magnesium Fights Depression Magnesium plays a critical role in brain function and mood, and low levels are linked to an increased risk of depression One analysis in over 8,800 people found that people under the age of 65 with the lowest magnesium intake had a 22% greater risk of depression. Some experts believe the low magnesium content of modern food may cause many cases of depression and mental illness; however, others emphasize the need for more research in this area. Nonetheless, supplementing with this mineral may help reduce symptoms of depression — and in some cases, the results can be dramatic. In a randomized controlled trial in depressed older adults, 450 mg of magnesium daily improved mood as effectively as an antidepressant drug. Anti-Inflammatory Benefits Low magnesium intake is linked to chronic inflammation (elevated C-reactive protein), which is one of the drivers of aging, obesity and chronic disease. Magnesium supplements can reduce CRP and other markers of inflammation in older adults, overweight people and those with prediabetes. In the same way, high-magnesium foods — such as fatty fish and dark chocolate — can reduce inflammation. Magnesium Improves PMS Symptoms Premenstrual syndrome (PMS) is one of the most common disorders among women of childbearing age. Its symptoms include water retention, abdominal cramps, tiredness and irritability. Interestingly, magnesium has been shown to improve mood, reduce water retention and other symptoms in women with PMS Magnesium Is Safe and Widely Available Magnesium is absolutely essential for good health. The recommended daily intake is 400–420 mg per day for men and 310–320 mg per day for women. You can get it from both food and supplements. Food Sources The following foods are good to excellent sources of magnesium: Pumpkin seeds: 46% of the RDI in a quarter cup (16 grams) Spinach, boiled: 39% of the RDI in a cup (180 grams) Swiss chard, boiled: 38% of the RDI in a cup (175 grams) Dark chocolate (70–85% cocoa): 33% of the RDI in 3.5 ounces (100 grams) Black beans: 30% of the RDI in a cup (172 grams) Quinoa, cooked: 33% of the RDI the in a cup (185 grams) Halibut: 27% of the RDI in 3.5 ounces (100 grams) Almonds: 25% of the RDI in a quarter cup (24 grams) Cashews: 25% of the RDI in a quarter cup (30 grams) Mackerel: 19% of the RDI in 3.5 ounces (100 grams) Avocado: 15% of the RDI in one medium avocado (200 grams) Salmon: 9% of the RDI in 3.5 ounces (100 grams) Supplements If you have a medical condition, check with your doctor before taking magnesium supplements. Though these are generally well-tolerated, they may not be safe for people who take certain diuretics, heart medications or antibiotics. Organixx's Magnesium 7: MAGNESIUM CHELATE This form of magnesium is especially important for muscle building, recovery, and health. [17] MAGNESIUM CITRATE Helps with the effects of obesity. In fact, one study found that this form helped arterial stiffness in healthy overweight individuals. MAGNESIUM BISGLYCINATE Often used to treat symptoms of excess stomach acid, such as stomach upset, heartburn, and acid indigestion. MAGNESIUM MALATE Some believe this to be the most bioavailable form of magnesium. It's found naturally in fruits, giving them a “tart taste.” Magnesium Malate can help with migraines, chronic pain, and depression. MAGNESIUM ASPARTATE This form helps the connection between your brain and muscles, your cardiac rhythms, and the overall acid-alkaline balance in your body. It also can support an elevated mood. It is absolutely essential in the metabolism of macronutrients, as well as the utilization of other minerals, B-complex vitamins, vitamin C and vitamin E. MAGNESIUM TAURATE This is the form of magnesium best for your heart. One study noted: “The complex magnesium taurate may thus have considerable potential as a vascular-protective nutritional supplement.” MAGNESIUM OROTATE While also helpful for the heart, magnesium orotate is believed to be the best form for metabolic improvements. This makes it a favorite for athletes seeking enhanced recovery, energy and performance. Resources: Organixx Magnesium 7 - Complete Full-Spectrum Daily Magnesium Supplement Magnesium and Human Health: Perspectives and Research Directions Volume 2018 |Article ID 9041694 J. Bertinato, C. Wu Xiao, W. M. Ratnayake et al., “Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men,” Food & Nutrition Research, vol. 59, no. 1, article 25974, 2015. U. Grober, J. Schmidt, and K. Kisters, “Magnesium in prevention and therapy,” Nutrients, vol. 7, no. 9, pp. 8199–8226, 2015. J. H. F. de Baaij, J. G. J. Hoenderop, and R. J. M. Bindels, “Magnesium in man: implications for health and disease,” Physiological Reviews, vol. 95, no. 1, pp. 1–46, 2015. Reported Dietary Intake, Disparity between the Reported Consumption and the Level Needed for Adequacy and Food Sources of Calcium, Phosphorus, Magnesium and Vitamin D in the Spanish Population: Findings from the ANIBES Study Suboptimal magnesium status in the United States: are the health consequences underestimated? Magnesium in Prevention and Therapy Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients The effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients Magnesium enhances exercise performance via increasing glucose availability in the blood, muscle, and brain during exercise Magnesium in depression Magnesium intake and depression in adults Rapid recovery from major depression using magnesium treatment Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures A pilot study on the effects of magnesium supplementation with high and low habitual dietary magnesium intake on resting and recovery from aerobic and resistance exercise and systolic blood pressure The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial Nutrition by Food Search: Magnesium - Fact Sheet for Health Professionals Chelated Magnesium Effects of magnesium citrate, magnesium oxide and magnesium sulfate supplementation on arterial stiffness in healthy overweight individuals: a study protocol for a randomized controlled trial Magnesium Glycinate A pilot study of magnesium aspartate hydrochloride (Magnesiocard®) as a mood stabilizer for rapid cycling bipolar affective disorder patients Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate Metabolic supplementation with orotic acid and magnesium orotate Magnesium enhances exercise performance via increasing glucose availability in the blood, muscle, and brain during exercise Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial 7 Serious Health Issues Linked to Magnesium Deficiency (+ How to Tell If You're Magnesium Deficient) What You Need to Know About Magnesium for Depression and Anxiety Magnesium for Better Sleep: Does it Help & What Type Do You Need?
国产抗新冠特效药来了丨Nation's Antibody Therapy Could be in Use SoonChina's domestically developed monoclonal neutralizing antibody therapy for COVID-19 treatment could be used clinically in the country within weeks after it was included in the country's Diagnosis and Treatment Protocol for COVID-19-adding a tool to the globalarsenal against the coronavirus.中国自主研发的抗新冠病毒安巴韦单抗/罗米司韦单抗联合疗法“特效药”为全球抗击新冠疫情“武器库”增添新法宝。在被纳入中国《新型冠状病毒感染的肺炎诊疗方案》后几周内,这款特效药就可以在国内投入临床使用。The global fight could also get a boost when the United States Food and Drug Administration makes a decision in one or two months on the application for emergency use authorization for the dual-antibody therapy, said Zhang Linqi, director of the Global Health and Infectious Diseases Research Center and Comprehensive AIDS Research Center at Tsinghua University's School of Medicine.清华大学医学院艾滋病综合研究中心主任、全球健康与传染病研究中心主任张林琦表示,如果美国食品药品监督管理局能在一两个月内就决定批准联合疗法的紧急使用授权申请,全球抗疫斗争也能得到推动。"It's a success of the cooperation among Brii Biosciences, Tsinghua University and the Third People's Hospital of Shenzhen, which have jointly developed the antibodies," said Zhang, who led the research team. "The team has accomplished a task within 20 months that usually takes 10 years."研究团队负责人张林琦说:“腾盛博药与清华大学、深圳市第三人民医院通力合作,才成功研发出抗体。团队在20个月内完成了一项通常需要10年时间的任务。” Monoclonal antibodies mimic those generated by the body to fight the virus that causes COVID-19. Antibody therapies can act more rapidly than the body's own process of making antibodies.单克隆抗体通过模拟人体产生的抗体对抗新冠病毒。抗体疗法的起效过程比人体自身产生抗体的过程更快。China's drug authority granted emergency approval for the antibody cocktail, administered via injections, on Dec 8, based on positive final and interim results from the phase 3 clinical trial with 847 enrolled outpatients around the world. The trial was sponsored by the US National Institutes of Health, according to Brii Biosciences, a multinational biotech company with offices in China and the US.基于第三期临床试验中全球847例入组患者的积极中期及最终结果,12月8日,国家药品监督管理局应急批准新冠病毒中和抗体联合治疗药物注射液的注册申请。据跨国生物技术公司腾盛博药称,试验由美国国立卫生研究院赞助。腾盛博药在中美皆设有办事处。Trial data found that the therapy could reduce the risk of hospitalization and death in high-risk patients by around 80 percent.试验数据发现,该疗法能够降低高风险新冠门诊患者近八成的住院和死亡风险。Regarding the emerging Omicron variant of the virus, Zhang said that in vitro pseudovirus testing data suggests that the therapy's combination of monoclonal neutralizing antibodies will work against Omicron and other variants.面对来势汹汹的新冠病毒变异株奥密克戎,张林琦表示,体外伪病毒属测试数据表明,联合疗法的单克隆中和抗体组合对奥密克戎及其他变体都有抑制作用。Moreover, the therapy can protect people, especially those whose physical condition doesn't allow vaccination, from becoming infected by COVID-19 for around nine to 12 months, he said.此外,张林琦表示,联合疗法可以让人们在大约9到12个月的时间里免疫新冠病毒,特别是那些身体状况不允许接种疫苗的人。Zhang, a veteran scientist in the fight against HIV/AIDS, said his previous experience helped a lot in the COVID battle.作为一位抗击抗艾资深科学家,张林琦表示他以前的经验在抗击新冠病毒的战斗中起了很大作用。"The whole development process of the new combination therapy will also contribute to future research and application of the HIV antibodies, which was like a big test for us," he said. "The team will continue to conduct research on better antibodies and strengthen the efficacy of the current therapy and make it more long-lasting."他说:“HIV对我们来说是一个巨大的考验,而新联合疗法的整个开发过程也会有助于HIV抗体未来的研究和应用。研究小组将继续研发更好的抗体,加强并延长目前治疗的效果。”He also said clinical application of the therapy faces challenges, including that production of monoclonal antibodies takes around two to three months.他还说,联合疗法的临床应用仍面临挑战,比如单克隆抗体的生产大约需要两到三个月。"To use the therapy efficiently and scientifically, the authorities need to make a good calculation of the quantity needed, and the company would then produce them based on orders," he said.他说:“为了科学有效地使用这种疗法,政府需计算好所需数量,然后公司根据订单生产药物。” Furthermore, monoclonal antibodies are usually expensive. Industry insiders said the Chinese government might include the combination therapy in the public health insurance program, though nothing has been decided.此外,单克隆抗体通常价格昂贵。业内人士表示,即使具体细则还未明确,中国政府也有可能会将联合疗法纳入公共医疗保险计划。Zhang, noting that China has used science and technology to fight COVID-19 since the beginning of the outbreak, said: "Science is the core to solving the issue. Science has shown its power in all sectors, from medical treatment, medicine and vaccine development to prevention and control measures."张林琦指出,自疫情爆发以来,中国就利用科学技术抗击新冠疫情,他说:“科学是解决这一问题的核心。科学在从医疗、医药、疫苗研发到疫情防控各个领域都显示出它的力量。” arsenal英 [ˈɑːsənl];美[ˈɑːrsənl] n. (统称)武器;兵工厂;武器库;军火库interim英 [ˈɪntərɪm];美[ˈɪntərɪm] adj. 临时的;过渡的;暂时的;期中的n. 间歇,过渡期间insider英 [ɪnˈsaɪdə(r)];美[ɪnˈsaɪdər] n. 知情人;知内情者;内部的人insurance英 [ɪnˈʃʊərəns];美[ɪnˈʃʊrəns] n. 保险;保险业;保险费;保费
Top headlines • Benchmarks end lower for a second day; Sensex slips 166 pts, Nifty holds 17,300 • NBFCs to come under the ambit of PCA framework from Oct 2022 • Shriram Transport Finance slumps 7% as analysts see limited near-term synergy after merger • Anand Rathi Wealth debuts at 9% premium • WPI-based inflation hits 12-year high of 14.2% in Nov • Data Patterns IPO sails through on first day Investors chose to stay on the sidelines for a second straight day on Tuesday as major central banks meet this week to assess risks from the new Omicron variant of coronavirus. The global balancing act will begin later today when the US Federal Reserve convenes its latest two-day meeting, and includes new monetary policy statements by the US central bank on Wednesday. Meanwhile, the European Central Bank and the Bank of England will meet on Thursday, and the Bank of Japan on Friday. That apart, studies that the Omicron variant has the potential to drive a further wave of infections, including among those already vaccinated, soured sentiment on the Street. Back home, India's annual wholesale price index-based inflation in November accelerated to 14.23 per cent, its highest level since April 2005, boosted by increase in manufacturing and food prices, fuelling concerns of rising inflationary pressure. All these triggers drove bulls away from the Street, taking benchmarks down by 0.3 per cent today. The BSE Sensex slipped 166 points to end at 58,117, while the Nifty50 closed 43 points lower at 17,325. In the intra-day deals, the BSE benchmark oscillated over 500 points and the Nifty swung 150 points. ITC, down nearly 3 per cent, was the top drag on the Sensex today after the company held its first ever analysts' meet. Among the notable announcements, ITC informed investors that it was redefining its portfolio, accelerating FMCG exports, considering digital as an area of investment, and was fuelling growth in hotel business. Bajaj Finance, Kotak Bank, Bharti Airtel, RIL, and Bajaj Finserv were some of the other top laggards. On the upside, Power Grid, Nestle India, Axis Bank, and Dr Reddy's Labs were the outperforming counters on the Sensex. In the broader markets, the BSE MidCap slipped 0.4 per cent, while the BSE Smallcap ended with minor gains. Among individual stocks, Anand Rathi Wealth listed at Rs 602.05, a 9 per cent premium over its issue price of Rs 550 per share, on the BSE. After listing, the stock moved higher to Rs 615 but pared gains to end at Rs 583.5, up 6 per cent over the issue price. The shares of Shriram Transport Finance plunged 7 per cent intra-day, to Rs 1,371 on the BSE, as most analysts saw limited near-term upside for the company after its proposed merger with Shriram Capital and Shriram City Union Finance. This was on the back of limited scope for synergies, given the varied nature of operating business segments and underlying customer base, analysts said. The shares of Lupin, meanwhile, surged 10 per cent to Rs 972.50 in intra-day trade after the drug-maker announced that it had received the Establishment Inspection Report from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility. The shares ended 6.6 per cent higher on the BSE. Among sectors, the Nifty Pharma index rallied 1 per cent, while the Nifty Realty and Financial Services indices slipped 0.7 per cent each. The Financials services sector, however, will be in focus tomorrow as the RBI has decided to bring NBFCs under its Prompt Corrective Action Framework from Oct 1, 2022. Now, let's recap primary market activity. The initial public offering of Data Patterns sailed through on the very first day and stood with 2.5 times subscription as at 3:30 PM. Further, the IPO of MedPlus Health has been subscribed 1.3 times so far on strong demand from retail investors and employees of the company. Lastly, the public issue of Rakesh Jhunjhunwala-backed Metro Brands ha
The United States Food and Drug Administration (FDA) is saying that it needs a full 75 years in order to fully release all data concerning the Pfizer and BioNTech vaccine against COVID-19. Previously, the FDA claimed it needed 55 years to release vaccine information such as safety, efficacy, test protocols, and adverse reaction reports, among other data. Read Full Article Here!
In a significant development this year, the United States Food and Drug Administration granted interchangeable status to two biosimilar drugs— Biocon's diabetes drug insulin glargine branded as Semglee and Boehringer Ingelheim's biosimilar Cyltezo. In this edition of The Medicine Box Podcast season 5, CNBC-TV18's Ekta Batra talks to Kiran Mazumdar-Shaw, the chairperson of Biocon, about Semglee, the first interchangeable biosimilar insulin product to have received approval from the US drug regulator for the treatment of diabetes. Interchangeability essentially means a pharmacist in the US can give a person the drug approved with an interchangeable status other than reference biologic on prescription. The development possibly paves the way for more life-saving drugs seeing greater accessibility and reducing price. Shaw also talks about Cyltezo, which is the biosimilar version of one of the world's largest selling biologic drugs Humira, used for arthritis and other conditions. Tune in to The Medicine Box Podcast to find out more about interchangeable biosimilars, their competition, prices, and more.
Dr. Renee Dufault is recognized as a biomedical expert in the areas of inorganic mercury and fructose toxicology, nutrition, autism, ADHD, epigenetics, and environmental hazard assessment. Her articles published in peer reviewed medical journals continue to be widely accessed and cited by other scientists. She is widely known for blowing the whistle on the United States Food and Drug Administration (FDA) when the agency attempted to block publication of her findings of inorganic mercury in high fructose corn syrup. To publish these findings, she retired early and gave up her career as a United States Public Health Service Officer. Websites foodingredient.info reneedufault.com Books Unsafe at Any Meal
Presenter:Hope S. Rugo MDProfessor of MedicineUniversity of CaliforniaSan Francisco Comprehensive Cancer CenterTNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.Follow along with the slideset located here:https://bit.ly/3krD3Gj
Our first episode shines a spotlight on a health center deep in America's Bible Belt. Albany Area Health Center serves a rural Georgia county that ranked 4th in the world for COVID-19 deaths per capita last summer. Their effort to battle the pandemic brought out the best in their community, but now they face the daunting challenge of vaccinating people who are undecided about the benefits of the vaccine. Hear how they're approaching the next phase in the pandemic.Key Takeaways:0:00 Intro1:18 Amy shares a short clip created by staff members from Albany Area Primary Health Care explaining how the pandemic hit them unexpectedly 2:43 Ronda shares a little bit of history about their health center, the population, whom they serve, and the challenges they have faced for the past 18 months addressing the pandemic 4:13 Ronda also talks about how far the nearest health center was to them and who they really are4:57 Pam talks about what she was thinking and feeling when the pandemic started to spread in their center quickly and they were in a good position before then 5:54 Ronda talks about why the State of Georgia has one of the lowest vaccination rates for Covid when they are declared an epicenter of Covid 7:48 Pam also shares some of the reasons she feels the State of Georgia has the lowest vaccination rates for Covid 9:37 Ronda and Pam talk about the number of vaccines they think they have administered already 10:21 Ronda also talks about how the vaccination hesitancy in the people that come to them to get vaccinated looks like and what they do to help them get over it 12:16 Ronda and Pam explain why it's the conversation that they have with people to help them get over the fear of being vaccinated that works and not one message 14:25 Pam talks about if having conversations with the community about the vaccine helped to get rid of the misinformation that they had about the vaccine 15:55 Ronda and Pam talk about the Pfizer vaccine for 12 and older people and the strategies that they are using to reach this population 17:25 Pam talks about the passionate group of physicians and nurses who are volunteering to partner with the health center to do the work 19:40 Ronda talks about switching from the mass vaccination site model to bringing shots to where the people are and how effective it is and if people are still coming to them 22:02 Pam shares her thoughts on the Biden Administration wanting to get about 70% of the Americans vaccinated by July fourth and if that will be possible 24:17 Ronda also shares her thoughts on if it will be possible for the Biden administration to vaccinate about 70% of the Americans by July fourth 27:20 Ronda and Pam talk about what they feel they bring to the table as a health center that is so important for a successful vaccination process 30:28 Pam shares the advice that she gives to the people who come to the health center for information and they are listening while they are on the fence 31:34 Ronda also shares her advice to people who are hesitant of getting the vaccination and what they should do 32:38 Pam and Ronda share some of their low and high points as providers and volunteers in the past 18 months of fighting the pandemic Shows Mentioned:Phoebe Putney Memorial Hospital is a better way to health and wellness. Our comprehensive network of physicians, nurses, and staff at three hospitals and more than 20 clinics delivers high-quality healthcare to the residents across Southwest Georgia.The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services.Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer.Quotes Mentioned:“The driving factor to get vaccinated or to not get vaccinated has been fear.”“There's no amount of education or information you can give to someone that fearful that's going to change their mind.”“Everything's very doable if you put enough energy into it.”“You have to be innovative and creative to get patients involved in their care.”“An informed decision is the best decision.”Guests Social Media Links:Ronda ArlineLinkedIn: https://www.linkedin.com/in/ronda-arline-8a36a21b2/ Website: https://aaphc.org/ Pam ReynoldsWebsite: https://aaphc.org/